Melatonin in Patients With Multiple Sclerosis (MS).
Status:
Active, not recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
To date, there are no published data on the role of melatonin supplementation or the
appropriate dose for patients with multiple sclerosis. Because of the potential benefits of
melatonin, this pilot study will be an exploratory investigation to evaluate the effect of
supplementing melatonin in subjects with multiple sclerosis who are taking an oral disease
modifying therapy (DMT) for 6 months or longer. It is our intent that the results of this
study will support the rationale and be a prelude to a larger trial which can focus on
clinical efficacy of melatonin therapy outcomes.